Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patie…

Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for ...
University of Delaware

Preparing for Final Exams

“Determine whether your final exam is cumulative or only information discussed in class since the most recent exam,” Volpe ...
The Manila Times

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine ...

A recent setback due to unexpected safety concern from a phase 2 study to evaluate a STAT3 inhibitor in IPF patients refreshed an old debate regarding the feasibility to develop therapeutics targeting ...
News-Medical.Net on MSN

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses.